MDA 2020 infographic: DMD: Examining the totality of evidence for corticosteroid treatment
Review real-world and clinical study data examining corticosteroid treatment for Duchenne muscular dystrophy (DMD) presented in our infographic distributed at MDA 2020
Understand the role of the immune system and inflammation as key components affecting the pathogenesis of DMD
The real-world implications of corticosteroid treatment for patients with DMD are presented
Find out more about the outcomes of the study with regard to loss of ambulation
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. PTC Therapeutics is the Marketing Authorization Holder for deflazacort in the US only. Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The US Prescribing Information for deflazacort is available here. Please refer to your local country guidance for more information.
For medical information, product complaints, or to report an adverse event, please call 1-866-562-4620 or email at email@example.com. You may also report adverse events directly to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Register now to unlock the content
Register now to access the content on this page
If not, register below
GL-DMD-0313 | June 2021
Sign in or register to access exclusive content on this site
Some cookies are essential, others help us improve your experience by providing insights into how the website is used. Select one or more of the cookie types listed below, and then save your preferences. Refer to our Cookies Statement for more information.
Performance cookies, which help us measure the website’s performance and improve your experience. In using performance cookies we do not store any personal data, and only use the information collected through these cookies in aggregated and anonymised form.